Far Infrared Irradiation for Stroke Rehabilitation - Full Text View

Purpose

A stroke is a sudden loss of brain function. It is caused by the interruption of flow of blood to the brain (ischemic stroke) or the rupture of blood vessels in the brain (hemorrhagic stroke). This study will investigate the use of far infrared radiation for stroke rehabilitation.

Condition	Intervention	Phase
Stroke	Radiation: Far Infrared Radiation	Phase I

MedlinePlus related topics:

Rehabilitation

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:

Management and Cure of Stroke [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Rehabilitation of the following: ability to move, see, remember, speak, reason and read and write. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Estimated Enrollment:	10
Study Start Date:	May 2008
Estimated Study Completion Date:	June 2010
Estimated Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Radiation: Far Infrared Radiation (5μm to 20μm wavelength)	Radiation: Far Infrared Radiation Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Detailed Description:

A stroke is a sudden loss of brain function. The interruption of blood flow or the rupture of blood vessels causes brain cells (neurons) in the affected area to die. The effects of a stroke depend on where the brain was injured, as well as how much damage occurred. A stroke can impact any number of areas including your ability to move, see, remember, speak, reason and read and write.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people with stroke.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

People with Stroke

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00675155

Locations


Canada, Ontario
	The Centre for Incurable Diseases
	Toronto, Ontario, Canada, M4V 1L5

Sponsors and Collaborators

GAAD Medical Research Institute Inc.

Investigators


Principal Investigator:	Francis Sam, M.D.	GAAD Medical Research Institute Inc.

More Information

Responsible Party:	GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder and President )
Study ID Numbers:	GAAD-SR-CTP1
First Received:	May 6, 2008
Last Updated:	October 7, 2008
ClinicalTrials.gov Identifier:	NCT00675155
Health Authority:	Canada: Health Canada; United States: Food and Drug Administration

Keywords provided by GAAD Medical Research Institute Inc.:

Apoplexy

Cerebral Stroke

Cerebrovascular Accident

Cerebrovascular Accident, Acute

Cerebrovascular Apoplexy

Cerebrovascular Stroke

Study placed in the following topic categories:

Cerebral Infarction

Stroke

Vascular Diseases

Brain Ischemia

Central Nervous System Diseases

Ischemia

Brain Infarction

Brain Diseases

Infarction

Cerebrovascular Disorders

Additional relevant MeSH terms:

Nervous System Diseases

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 23, 2008

Sponsored by:	GAAD Medical Research Institute Inc.
Information provided by:	GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:	NCT00675155